US FDA approves Merck’s anti-PD-1 therapy for endometrial carcinoma patients

Keytruda is approved as a single agent to treat advanced endometrial carcinoma patients. Credit: Copyright © 2009-2022 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.